Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auriel-RA: Idacio vs Humira in Rheumatoid Arthritis
NCT03052322Phase 3Completed
- Sponsor
- Fresenius Kabi
- Start
- Jan 2017
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Fresenius Kabi. Primary endpoint: Treatment-emergent Adverse Events of Special Interest at 52 weeks. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03052322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052322.